PolyPeptide Group (PPGN) Stock Overview
Operates as a contract development and manufacturing company in Europe, the United States, and India. More details
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 4/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
PPGN Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Biotech longerterm bet
PolyPeptide Group AG Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CHF 26.00 |
| 52 Week High | CHF 33.40 |
| 52 Week Low | CHF 13.22 |
| Beta | 1.11 |
| 1 Month Change | 9.70% |
| 3 Month Change | 6.12% |
| 1 Year Change | -9.41% |
| 3 Year Change | -7.41% |
| 5 Year Change | n/a |
| Change since IPO | -66.75% |
Recent News & Updates
PolyPeptide Group (VTX:PPGN) Is Carrying A Fair Bit Of Debt
Sep 25
Earnings Update: Here's Why Analysts Just Lifted Their PolyPeptide Group AG (VTX:PPGN) Price Target To CHF31.29
Aug 16PolyPeptide Group AG's (VTX:PPGN) Shares Leap 28% Yet They're Still Not Telling The Full Story
Aug 15Recent updates
PolyPeptide Group (VTX:PPGN) Is Carrying A Fair Bit Of Debt
Sep 25Earnings Update: Here's Why Analysts Just Lifted Their PolyPeptide Group AG (VTX:PPGN) Price Target To CHF31.29
Aug 16PolyPeptide Group AG's (VTX:PPGN) Shares Leap 28% Yet They're Still Not Telling The Full Story
Aug 15Does PolyPeptide Group (VTX:PPGN) Have A Healthy Balance Sheet?
May 23PolyPeptide Group AG (VTX:PPGN) Might Not Be As Mispriced As It Looks After Plunging 28%
Apr 08Why PolyPeptide Group AG (VTX:PPGN) Could Be Worth Watching
Feb 04Many Still Looking Away From PolyPeptide Group AG (VTX:PPGN)
Jan 09PolyPeptide Group AG's (VTX:PPGN) Intrinsic Value Is Potentially 19% Below Its Share Price
Nov 11PolyPeptide Group (VTX:PPGN) Is Making Moderate Use Of Debt
Oct 21Sentiment Still Eluding PolyPeptide Group AG (VTX:PPGN)
Sep 16Does PolyPeptide Group (VTX:PPGN) Have A Healthy Balance Sheet?
Jun 19Further Upside For PolyPeptide Group AG (VTX:PPGN) Shares Could Introduce Price Risks After 33% Bounce
Mar 14PolyPeptide Group AG's (VTX:PPGN) Intrinsic Value Is Potentially 99% Above Its Share Price
Mar 13PolyPeptide Group AG Earnings Missed Analyst Estimates: Here's What Analysts Are Forecasting Now
Mar 18Investors Shouldn't Be Too Comfortable With PolyPeptide Group's (VTX:PPGN) Robust Earnings
Mar 23Shareholder Returns
| PPGN | CH Life Sciences | CH Market | |
|---|---|---|---|
| 7D | 9.0% | 5.6% | 0.004% |
| 1Y | -9.4% | -3.2% | 2.6% |
Return vs Industry: PPGN underperformed the Swiss Life Sciences industry which returned -3.2% over the past year.
Return vs Market: PPGN underperformed the Swiss Market which returned 2.6% over the past year.
Price Volatility
| PPGN volatility | |
|---|---|
| PPGN Average Weekly Movement | 6.8% |
| Life Sciences Industry Average Movement | 4.5% |
| Market Average Movement | 3.4% |
| 10% most volatile stocks in CH Market | 7.4% |
| 10% least volatile stocks in CH Market | 1.7% |
Stable Share Price: PPGN's share price has been volatile over the past 3 months compared to the Swiss market.
Volatility Over Time: PPGN's weekly volatility (7%) has been stable over the past year, but is still higher than 75% of Swiss stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1952 | 1,400 | Juan Gonzalez | www.polypeptide.com |
PolyPeptide Group AG operates as a contract development and manufacturing company in Europe, the United States, and India. It develops and manufactures synthetic peptides and oligonucleotides used as active pharmaceutical ingredients or intermediates in therapeutic products for pharmaceutical and biotech companies. The company offers portfolio of drug therapies for metabolic diseases, including the GLP-1.
PolyPeptide Group AG Fundamentals Summary
| PPGN fundamental statistics | |
|---|---|
| Market cap | CHF 857.78m |
| Earnings (TTM) | -CHF 32.11m |
| Revenue (TTM) | CHF 341.19m |
Is PPGN overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| PPGN income statement (TTM) | |
|---|---|
| Revenue | €368.85m |
| Cost of Revenue | €327.33m |
| Gross Profit | €41.52m |
| Other Expenses | €76.24m |
| Earnings | -€34.72m |
Last Reported Earnings
Jun 30, 2025
Next Earnings Date
Mar 12, 2026
| Earnings per share (EPS) | -1.05 |
| Gross Margin | 11.26% |
| Net Profit Margin | -9.41% |
| Debt/Equity Ratio | 27.3% |
How did PPGN perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/10/26 08:55 |
| End of Day Share Price | 2025/10/24 00:00 |
| Earnings | 2025/06/30 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
PolyPeptide Group AG is covered by 15 analysts. 5 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Leonildo Delgado | Baader Helvea Equity Research |
| Volker Bosse | Baader Helvea Equity Research |
| Markus Mayer | Baader Helvea Equity Research |